scPharmaceuticals Extends Supply Agreement with West Pharmaceutical Services Until 2027

Reuters
Aug 25, 2025
scPharmaceuticals Extends Supply Agreement with West Pharmaceutical Services Until 2027

scPharmaceuticals Inc. has announced an amendment to its existing Supply Agreement with West Pharmaceutical Services, Inc. The agreement, originally signed on August 15, 2020, involves the purchase of West's SmartDose® drug delivery system. Under the new terms, the agreement will remain in effect until December 31, 2027, with no provisions for automatic extension or renewal. Additionally, if either party opts to terminate the agreement, scPharmaceuticals will be responsible for covering any costs incurred and purchase orders accepted up to the termination date. This amendment marks a significant step in the continued collaboration between the two companies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. scPharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-186947), on August 25, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10